Articles from Remix Therapeutics

WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Stifel 2025 Virtual Targeted Oncology Forum on Tuesday, April 8, 2025, at 1:00 p.m. ET.

WATERTOWN, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that its management team will host one-on-one meetings with investors at the Leerink Global Healthcare Conference on Monday, March 10, 2025 in Miami, FL.

Company to Announce Lead Program During Podium Presentation